Urolithiasis in patients with inflammatory bowel diseases

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10314602" target="_blank" >RIV/00216208:11110/15:10314602 - isvavai.cz</a>
Result on the web
<a href="http://www.prolekare.cz/linkout/56940" target="_blank" >http://www.prolekare.cz/linkout/56940</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14735/amgh2015561" target="_blank" >10.14735/amgh2015561</a>

Result language
angličtina
Original language name
Urolithiasis in patients with inflammatory bowel diseases
Original language description
Inflammatory bowel diseases are typically accompanied by diarrhoea and malabsorption, both of which are predispos-ing factors for the formation of renal calculi. In patients who have not undergone bowel surgery the prevalence of urolithiasis has ranged from 1.5% to 5%, but after surgery stone prevalence can increase to up to 16%. Enteric hyperoxaluria is a frequent complication of inflammatory bowel diseases, ileal resection and Roux-En-Y gastric bypass and is a recognised cause of nephrolithiasis and nephrocalcinosis. The excess of oxalate is primarily excreted by the kidneys. Increased urinary excretion of oxalate results in urinary calcium oxalate supersaturation, leading to crystal aggregation, urolithiasis, and/ or nephrocalcinosis. Prevention ofoxalate lithiasis includes high fluid intake, prescription of oral citrate and magnesium, calcium supplement, nutritionally balanced low-oxalate low-fat diet and also biological manipulation of intestinal flora (Oxalobacter formigenes, Bi
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)